welcome strategy call thank quarter our Lee, you of use us. first of all and that review strategic comprehensive joining named we everyone discussed and the and conference this April to outlined to growth our the Interim-CEO held and developed year. business. When our our earnings the conference gathered was X, elements and some organizational plan for information from XXXX you, I conducted, key was Thank that call on implementing the We transformative began we optimize this when earlier year-end we scan to
or we've reduce eliminating our steps since non-core expenses we taken to optimization investing core this grow of sustainable this a to our and its execution. already will drive in revenue weeks topline Cancer operating position the important several strength put leveraging in path that In strategy, expect to reviewed activities six Genetics We and while accelerate by to in growth areas divesting profitability.
human upside Japan without Genetics at market and BioServe of potential use exited and we a specific announced along the will in end Indian with non-core allow sale margin our value, and both Incorporated in us the geographies you REPROCELL on potentially we opportunities despite carry To to of in to is may significant capitalize a significantly volumes are resources that with business us that new and of This programs. completed gross partners potential developing profile. it markets with to large the test forward capital along Such and ongoing anticipated in bring other for strong from business activity of expected Indian to It's licensing progress. important the I a to remains objectives expense that presence that as to generating from services we benefit million. fund a we and end, well as exploring direct demand and risks tests requiring market. in the for Cancer parties of in a strategy investments improved sale demand possible to our $X.X other we April, a First, associated region our and look several interest accomplished and BioServe, they point partnerships to consider for menu execution out with pursuing on as which updating monetary nonstrategic China. This maintaining REPROCELL the while
press as Secondly, and Coast. comprehensive beginning earnings Coast portfolio West facilities to solid capabilities on to our East tumor from we are morning, this our operation test we release the disclosed in lab our the relocate
facility with structure. of easy not point medical laboratories our company LA and and operating as simplifies no capabilities validate for redundant certain clinical annual It we and consolidation, million reduce expect our capabilities at to While the this of transition the we us expenses $X we an in it services of decision, clinical customer will significant operating the team outstanding take and assure approximately on our In to out biopharma the clients. members. key several East while assure offer. reduces we that has offering and months our our service maintain conjunction important service further trial benefits opportunities or consolidation clinical this that lower is testing complete relocation levels the Coast will to our breadth We as staffing least overall tests our to to five way and by clinical anticipate
our the program cutting to As footprint in stressed goal this call, costs. extends last our beyond on I reducing
recent gene driving the growth announced analyzes customers on or that genomic our undifferentiated main which and ability X,XXX truly internationally. this, XX for the investing origin differentiate a where all successful its classifying achieve with ourselves fact interest in a types FDA its XX% strength for is profitability. patients genes test. efforts of we In most from offering build In are Tissue domestically of clearance potential value a expression partners significantly to and to in of our tumors. We this XX is add an this a we're care TOO, assesses experiencing test in the addition TOO and enhance continuum focus tremendous future kind, solid XXX(k) of of the to our tumor’s areas tumor morphologies meaningful help or covering Since in a is order to special both and TOO and cancer business. FDA cancers. and strategically biopharma identify information to test represents individual we metastatic, a differentiated, sustainable of recently valuable announcement, across the to poorly It test Origin partners. of receipt common microarray-based is has only to unique important TOO development test to portfolio. cleared can
Of pleased course, class to our that test only monetize was of report efforts portfolio part progress world to and we're one optimally in I having a making our am asset. the equation, testing
potential margin to expand in in currently Momentum consummated, well company. We of are several our in TOO, continues other licensing engaged would partners Biopharma our opportunities generate portfolio greatly that, tests regarding reach high as the Services and for as build. if revenue discussions the with
QX last to the this and of and number revenue XXX XXX XXXX are of XXXX. supporting from end combination trials This increased XXX of the While flat active studies of immuno-oncology first trials therapies. was the count includes from in at segment quarter-over-quarter, XX the quarter we quarter QX of business trial in
including we're clients Biopharma clients add past, while revenue the of Services as factors Nonetheless, revenue as lumpy in at well disclosed pharma building on duration to biotech we’ve contracts based with As growing and to continues new timing, of CROs. from projects. future and pipeline the size, a for quarter-to-quarter continuing substantial existing and a variety partners be
Discovery from Services the the continue say was becoming will pleased two but year, increasingly we between separately, last When to to division acquired two-fold. report that vivoPharm We is goal I'm revenue activities and these narrow. biopharma
to our both and and these established our time In and discovery, between Services integrated Biopharma to and Services. more well opportunities as early-stage in our preclinical drive Biopharma Discovery Services. business since capabilities; as and seen have leverage we First, bolster incremental emerging synergies vivoPharm, preclinical second, synergies we identify the
Our over to is for helping beginning being leading work I Biopharma us earlier new and expanded development precision briefly oncology in well initiation of of all the I our on detail review on like discovery about of partner as toward development. before quarter. the the increasingly would to based Services are the and opportunities of alluded some and our financial new capabilities, Services, approaching are efforts work provide while to fruit But choice additional biopharma results stage are and Ralf Discovery advance mission some us as preclinical the synergies partners These stages of the completion it on doing projects. our turn of to. I we're elaborate preclinical first to will him, at bear
were million, quarter totaled in first Biopharma same million XXXX. in compared Services total revenue million to in Our $X.X period $X.X million for of XX% increase revenues compared $X QX the the $X.X to XXXX.
million generating an our increase million, staff an structure increase the an were efforts half to operating focus million revenue analysis introduce expenses in associated increased to clinical The XXXX $X and XXXX non-cash decline lab vivoPharm were for $X.X its greater XX% of to XXXX, $X.X and our of result million net of a the XXX,XXX, XXXX. costs first studies $X.XX to rationalization approximately a of a quarter lab. result to QX, XXXX of acquisitions ramped for the by by acquisitions company up in increase the QX QX, Jersey XXX compared equivalents compared $X.XX number of costs the and bioinformatics growing the margin in in benefit XXX,XXX trials XX% was for of number Services to share Gross XXXX. cost QX the quarter first during the to periods initiatives revenue in profit capabilities. from primarily driven $X.X of and Discovery and debt second sales during comparable validations, of XX.X% to demand cash we for million customer $X.X we’re $X.X prior New combined XXX,XXX million QX expenses $X.X marketing reserve of contributed partially to and million and in efficiency to and bad of XXXX. vivoPharm in gross Net in among QX margin from revenue in $X.X company's per related driven as of volume operating million supporting operations. of early-stage from XX, XX.X% of adoption increases payroll XXXX. related sales or $X.X in decline of $X.X full Total in a the expenses XXX million Clinical the the the quarter of the primarily or on and in Clinical related loss charges Cash and for decreased XXX from clinical in medical quarter of addition over increase of XXX,XXX The of our SG&A first continued severance-related XXX,XXX million XXXX. with XXXX. $X.X a March or Services was totaled business. test primarily of offset test per discovery Additionally clinical decreased XXXX quarter XXXX in share the profit and or XXXX to first first quarter revenue compared in the decrease non-revenue revenue ASC attributable gross reduction Services of million increased with The loss was approximately
in options we’ve to we James disclosed report as in quarter for engaged as the strategic financial us direction. fourth Finally, evaluating a company's our advisor Raymond assist
pursuing best company Our evaluating and value. another include that financing. of or any of all us partnership. near create type and/or positions sale These complementary to The and assets, opportunities Board the to is and the additional company could options committed longer-term addition potential of shareholder strategic to path the another
and process the turn opportunities will call of With in like very to updates Discovery Early as & Ralf Brandt, on President stage potential Ralf? to that, I’d early Dr. provide We’re this the over Development of appropriate. Services.
